CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
ID: 356935Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356935

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-077.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System." This initiative invites applications for basic research projects focused on understanding the mechanisms of toxicity of chemical warfare agents and toxic industrial chemicals that impact the nervous system, with the aim of developing potential therapeutic countermeasures for civilian exposure. The program is particularly significant in enhancing public health responses to chemical threats, emphasizing innovative and transdisciplinary research approaches. Up to four grants totaling $2 million are anticipated for fiscal year 2026, with applications due by 5 PM local time on October 17, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-077-Full-Announcement.html
    PAR-25-077.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity (NOFO) titled "NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System." This initiative, reissuing PAR-24-030, seeks applications focused on basic research related to chemical warfare agents and toxic industrial chemicals that impact the nervous system. The primary objective is to enhance understanding of the mechanisms of toxicity, leading to potential therapeutic countermeasures for civilian exposure. Up to four grants totaling $2 million are anticipated for FY 2026, with applications due by 5 PM local time on October 17, 2026. Eligible applicants include various educational institutions and organizations, with an emphasis on innovative, transdisciplinary research. The proposal must adhere to rigorous scientific standards, and applicants are encouraged to outline experimental designs that minimize biases. Additionally, research must focus on acute exposure effects rather than chronic conditions. This funding opportunity aligns with NIH’s goal of improving public health responses to chemical threats while fostering collaborations among researchers. Applicants should ensure compliance with NIH policies and are advised to complete necessary registrations in advance.
    Similar Opportunities
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) program, focusing on basic research related to chemical warfare agents and toxic industrial chemicals that impact the nervous system. The objective is to elucidate mechanisms of toxicity, identify biological markers, and develop potential therapeutic countermeasures for civilian populations exposed to these chemicals. This funding opportunity is critical for enhancing public safety against chemical threats, with a total of $2 million available for up to four awards, each with a maximum annual budget of $300,000 over three years. Interested applicants must submit their proposals by September 17, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Countermeasures Against Chemical Threats (CounterACT) initiative, focusing on the early-stage development of therapeutics to address health impacts from toxic chemical exposure. This funding opportunity aims to foster collaborations and innovative projects that can effectively mitigate adverse health effects, with an emphasis on the UG3/UH3 activity code for phased development. The NOFO is anticipated to be released in early 2025, with applications due by October 2025, and awards expected to be made by June 2026, marking a significant investment in public health safety. Interested applicants should prepare to align their proposals with the outlined objectives and timelines.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin," aimed at funding fundamental research on skin injuries caused by chemical threats recognized as public health risks. The initiative seeks to enhance understanding of the mechanisms leading to chemical-induced skin injuries and to identify potential therapeutic targets for medical countermeasure development, with a focus on examining two or more Chemicals of Concern, including at least one vesicant. This funding opportunity is crucial for advancing knowledge in the field of chemical threat response and wound healing, with an estimated funding amount of $1.25 million available for fiscal year 2025, allowing for up to five awards capped at $225,000 per year. Applications will open on January 16, 2025, and interested parties can direct inquiries to grantsinfo@nih.gov for further information.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Chemical Countermeasures Research Program (CCRP) Initiative, aimed at supporting research on the harmful effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids, such as fentanyl and carfentanil. This initiative seeks to advance understanding of both immediate and delayed health impacts associated with these substances, emphasizing innovative research into toxicity mechanisms and the development of new therapeutic strategies. The program will provide up to four grants, with a maximum award of $300,000 annually over a potential five-year period, totaling an estimated $2 million in funding. Interested applicants, including various educational and nonprofit institutions, must submit their proposals by November 18, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The NOFO is expected to be published in Fall 2024, with applications due in Winter/Spring 2025, and will offer a funding ceiling of $450,000. Interested applicants should prepare to submit their proposals by the estimated close date of February 16, 2025, with awards anticipated to be made by December 1, 2025.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at developing broad-spectrum products to counteract Botulinum Neurotoxin (BoNT) intoxication. The initiative seeks to support the creation of therapies that can effectively reverse the effects of BoNT, addressing the limitations of current treatments, which primarily rely on passive immunoglobulin therapy. This funding opportunity utilizes a milestone-driven, biphasic R61/R33 award mechanism, with up to $2.9 million available for 5-6 awards in the R61 phase, focusing on feasibility studies before transitioning to further development in the R33 phase. Interested applicants, including various educational and community organizations, must adhere to NIH's review criteria and submit proposals by May 2, 2025. For more information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-080.html.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.